Investor Class Action Filed Against NewLink Genetics Corporation for Securities Fraud Violations
Company Name: NewLink Genetics Corporation
Court: United States District Court for the Southern District of New York
Case Number: 16-cv-03545
Judge: The Hon. William H. Pauley III
Class period: Between September 17, 2013 and May 9, 2016
Security Type:

Case Background:

On May 12, 2016, the initial complaint in this securities class action was filed against NewLink Genetics Corporation (“NewLink” or the “Company”), and certain of NewLink’s directors and officers, asserting violations of sections 10(b) and 20(a) of the Securities Exchange Act. The Complaint alleges that throughout the class period, defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company’s algenpantucel-L treatment was ineffective and potentially harmful to patients; and (ii) as a result of the foregoing, NewLink’s public statements were materially false and misleading at all relevant times.

Current Status of Case:

On July 31, 2018, defendants filed a Motion to Dismiss the Second Amended Complaint. On February 13, 2019, the Court issued an Order granting defendants' Motion to Dismiss.  On March 14, 2019, Lead Plaintiffs appealed that decision to the United States Court of Appeals for the Second Circuit.  On July 13, 2020, the Second Circuit affirmed in part and reversed in part the District Court's dismissal Order, and the case was remanded back to the District Court for further proceedings. 

This action is still ongoing. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.

Kessler Topaz Meltzer & Check, LLP
James Maro, Esq. or Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087 1-844-887-9500 (toll free) or 1-610-667-7706
Or by e-mail at

Please complete this form and list your purchase and sale transaction(s) for NewLink Genetics Corporation (NASDAQ: NLNK) between September 17, 2013 and May 9, 2016, inclusive (the “Class Period”):

You may also contact James Maro, Jr., Esq. or Adrienne Bell, Esq. at 610.667.7706 or toll free at 844.887.9500, or you may submit your information via email at, or you may click here to print a PDF of this form.

* Denotes required field
# of Shares
Price per Share
Principal Amount
Amount Paid
Series or CUSIP
# of Contracts
Price per Contract
Exercise Price
Expiration Date
Did you purchase shares of NewLink Genetics Corporation (2016) prior to the Class Period?
Are you a current or former employee of NewLink Genetics Corporation (2016)?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.
I agree to the KTMC
I would like to receive
new case alerts by email